|
New Genzyme Gaucher’s Candidate Meets Phase III Endpoint
Genzyme’s Phase III trial of eliglustat tartrate to treat Gaucher’s disease Type 1 has met its endpoint, setting the company up for a filing in the fourth quarter.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives